The teams of Shinya MINATO at Gifu University and Mari DEZAWA of Tohoku University have confirmed in rabbit tests that Muse cells (pluripotent stem cells) migrated to an infarct site and engrafted, differentiating into cardiomyocytes, and exerting effects such as cardiac function improvement for more than half a year. With allogenic MUSE cells, from other rabbits or humans, similar effects were observed. As Muse cells can differentiate into multiple cell types, they are candidate stem cells for the treatment of myocardial or cerebral infarction, hepatopathy, or renal failure. They repair injured sites and restore function. Phase I clinical tests are presently initiated by Mitsubishi’s Life Science Institute (LSI Medience) at Gifu University.

Nikkei Biotech news release, March 7, 2018